Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Knapp

Showing results (421-430 of 451) with videos related to

Pageof 46
Sort By:
Age and Ageing|February 11, 2020
Factors associated with self- and informant ratings of quality of life, well-being and life satisfaction in people with mild-to-moderate dementia: results from the Improving the experience of Dementia and Enhancing Active Life programmeYu-Tzu Wu, Sharon M Nelis, Catherine Quinn, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Plos One|November 30, 2023
Psychosis Recovery Orientation in Malawi by Improving Services and Engagement (PROMISE) protocolStephen Lawrie, Charlotte Hanlon, Lucinda Manda-Taylor, et al.
International Journal of Geriatric Psychiatry|July 11, 2023
Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: A systematic mapping of 340 randomised controlled trialsMaximilian Salcher-Konrad, Cheng Shi, Disha Patel, et al.
Journal of Neurology|October 17, 2002
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathyGiancarlo Comi, Luisa Roveri, Antony Swan, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Pageof 46

Showing results (421-430 of 451) with videos related to

Sort By:
Pageof 46
Age and Ageing|February 11, 2020
Factors associated with self- and informant ratings of quality of life, well-being and life satisfaction in people with mild-to-moderate dementia: results from the Improving the experience of Dementia and Enhancing Active Life programmeYu-Tzu Wu, Sharon M Nelis, Catherine Quinn, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Plos One|November 30, 2023
Psychosis Recovery Orientation in Malawi by Improving Services and Engagement (PROMISE) protocolStephen Lawrie, Charlotte Hanlon, Lucinda Manda-Taylor, et al.
International Journal of Geriatric Psychiatry|July 11, 2023
Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: A systematic mapping of 340 randomised controlled trialsMaximilian Salcher-Konrad, Cheng Shi, Disha Patel, et al.
Journal of Neurology|October 17, 2002
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathyGiancarlo Comi, Luisa Roveri, Antony Swan, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Pageof 46